Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 171Fallopian Tube Neoplasms 85Uterine Cervical Neoplasms 40Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Neoplasms 14Peritoneal Neoplasms 10Colorectal Neoplasms 9Brenner Tumor 9Breast Neoplasms 9Stomach Neoplasms 8Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Diseases 3Melanoma 3Glioblastoma 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Vaccinia 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × Bevacizumab × Gynecologic × Clear all
NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

West China Second University Hospital

Phase 2 Not yet recruiting
39 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡